Abstract
Thomas Bollyky explains the emerging controversy over patented medicines for noncommunicable diseases and their affordability in developing countries. Another transformation in global health is required that focuses on low-cost interventions and patient-centered, rather than country-focused, strategies.
Please see later in the article for the Editors' Summary
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Developing Countries*
-
Global Health / economics
-
Global Health / legislation & jurisprudence*
-
Global Health / standards
-
Health Services Accessibility*
-
International Cooperation / legislation & jurisprudence
-
Legislation, Drug / standards
-
Patents as Topic*
-
Pharmaceutical Preparations / economics
-
Pharmaceutical Preparations / supply & distribution*
Substances
-
Pharmaceutical Preparations
Grants and funding
The author was salaried during writing by his employer, the Council on Foreign Relations. No specific funding was set aside or given for the writing of this paper. No funding bodies had any role in the writing, interviews, data collection and analysis, decision to publish, or preparation of the manuscript.